Renard-Penna Raphaele, Cancel-Tassin Geraldine, Comperat Eva, Roupret Morgan, Mozer Pierre, Cussenot Olivier
UPMC University Paris 06, GRC No. 5, ONCOTYPE-URO, Paris, France.
World J Urol. 2015 Jul;33(7):929-36. doi: 10.1007/s00345-015-1570-z. Epub 2015 May 6.
According to recent reports from randomized studies comparing radical treatment or watchful waiting, the outcome of localized prostate cancer remains uncertain at individual level. It is especially true for the low-risk group (according D'Amico or CAPRA classifications), regarding the individual exposition to overtreatment by radical therapies or the opposite risk of under-treatment with active surveillance.
In this review, we describe the available molecular predictor tests and functional MRI, as well as their potential role in the selection of the appropriate treatment for prostate cancer patients.
The recent development of functional MRI imaging and clinical practice approval of molecular predictor tests for the assessment of the aggressive prostate cancer have brought new perspectives for the management of localized prostate cancer by active surveillance, focal ablative therapy or radical therapies.
根据近期比较根治性治疗与观察等待的随机研究报告，局部前列腺癌在个体层面的治疗结果仍不确定。对于低风险组（根据达米科或CAPRA分类）而言，情况尤其如此，因为个体面临根治性治疗过度治疗的风险，或相反的主动监测治疗不足的风险。
在本综述中，我们描述了现有的分子预测检测和功能磁共振成像，以及它们在为前列腺癌患者选择合适治疗方法中的潜在作用。
功能磁共振成像的最新进展以及用于评估侵袭性前列腺癌的分子预测检测的临床实践批准，为通过主动监测、局部消融治疗或根治性治疗来管理局部前列腺癌带来了新的视角。
